Erratum to “Desmoid Fibromatosis in Pediatric Patients: Management Based on a Retrospective Analysis of 59 Patients and a Review of the Literature”

Table 3

Efficacy of 61 chemotherapy regimens in 32 patients with measurable disease during first or any subsequent line of therapy.

	𝑁	CR	PR	Overall response (%)	SD	PD	Unknown response (%)
VA	6	—	1	1 (17%)	5	—	—
IVA	13	3	1	4 (30%)	9	—	—
VAC	3	—	—	—	1	1	1
VAC and tamoxifen	1	—	—	—	1	—	—
Vinblastine-MTX	14	—	7	7 (50%)	5	1	1
Vinblastine-MTX-tamoxifen	7	—	3	3 (43%)	3	—	1
Doxorubicin with other agents*	5	—	2	2 (40%)	—	3	—
Imatinib mesylate	2	—	—	—	2	—	—
Others^+	10	—	2	2 (20%)	1	7	—
Total	61	3	16	19 (31%)	27 (44%)	12 (20%)	3 (5%)

VA: vincristine and dactinomycin; IVA: ifosfamide, vincristine and dactinomycin; VAC: vincristine, dactinomycin, and cyclophosphamide; MTX: methotrexate. 𝑁: number of patients; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease.
*Doxorubicin with vincristine, cisplatin, ifosfamide, cyclophosphamide, or tamoxifen.
⁺Others: VINCAEPI (vincristine, carboplatin, and VM 26), MMT95 protocol (IVA, etoposide, epirubicin, and carboplatin), dactinomycin alone, etoposide-ifosfamide, etoposide alone, and carboplatin.